Cargando…
Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation
In this study, the effects of cinnamaldehyde and curcumin on Akt2, a serine/threonine protein kinase central to the insulin signaling pathway, were examined in preadipocytes. Cinnamaldehyde or curcumin treatment increased Akt2 phosphorylation at multiple sites including T450 and Y475, but had no eff...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416494/ https://www.ncbi.nlm.nih.gov/pubmed/36014807 http://dx.doi.org/10.3390/nu14163301 |
_version_ | 1784776494127513600 |
---|---|
author | Urasaki, Yasuyo Le, Thuc T. |
author_facet | Urasaki, Yasuyo Le, Thuc T. |
author_sort | Urasaki, Yasuyo |
collection | PubMed |
description | In this study, the effects of cinnamaldehyde and curcumin on Akt2, a serine/threonine protein kinase central to the insulin signaling pathway, were examined in preadipocytes. Cinnamaldehyde or curcumin treatment increased Akt2 phosphorylation at multiple sites including T450 and Y475, but had no effect on Akt2 phosphorylation at S474, which is critical for Akt2 activation. Surprisingly, insulin treatment with cinnamaldehyde or curcumin increased p-Akt2 (S474) by 3.5-fold versus insulin treatment alone. Furthermore, combined cinnamaldehyde, curcumin, and insulin treatment increased p-Akt2 (S474) by 7-fold versus insulin treatment alone. Interestingly, cinnamaldehyde and curcumin inhibited both serine/threonine phosphatase 2A (PP2A) and protein tyrosine phosphatase 1B (PTP1B). Akt2 activation is a multistep process that requires phosphorylation at T450 for proper folding and maturation, and phosphorylation of both Y475 and S474 for stabilization of the catalytic domain. It is plausible that by inhibiting PP2A and PTP1B, cinnamaldehyde and curcumin increase phosphorylation at T450 and Y475, and prime Akt2 for insulin-stimulated phosphorylation at S474. Notably, the combination of a PP2A inhibitor, okadaic acid, and a PTP1B inhibitor increased p-Akt2 (S474), even in the absence of insulin. Future combinations of PP2A and PTP1B inhibitors provide a rational platform to engineer new therapeutics for insulin resistance syndrome. |
format | Online Article Text |
id | pubmed-9416494 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94164942022-08-27 Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation Urasaki, Yasuyo Le, Thuc T. Nutrients Article In this study, the effects of cinnamaldehyde and curcumin on Akt2, a serine/threonine protein kinase central to the insulin signaling pathway, were examined in preadipocytes. Cinnamaldehyde or curcumin treatment increased Akt2 phosphorylation at multiple sites including T450 and Y475, but had no effect on Akt2 phosphorylation at S474, which is critical for Akt2 activation. Surprisingly, insulin treatment with cinnamaldehyde or curcumin increased p-Akt2 (S474) by 3.5-fold versus insulin treatment alone. Furthermore, combined cinnamaldehyde, curcumin, and insulin treatment increased p-Akt2 (S474) by 7-fold versus insulin treatment alone. Interestingly, cinnamaldehyde and curcumin inhibited both serine/threonine phosphatase 2A (PP2A) and protein tyrosine phosphatase 1B (PTP1B). Akt2 activation is a multistep process that requires phosphorylation at T450 for proper folding and maturation, and phosphorylation of both Y475 and S474 for stabilization of the catalytic domain. It is plausible that by inhibiting PP2A and PTP1B, cinnamaldehyde and curcumin increase phosphorylation at T450 and Y475, and prime Akt2 for insulin-stimulated phosphorylation at S474. Notably, the combination of a PP2A inhibitor, okadaic acid, and a PTP1B inhibitor increased p-Akt2 (S474), even in the absence of insulin. Future combinations of PP2A and PTP1B inhibitors provide a rational platform to engineer new therapeutics for insulin resistance syndrome. MDPI 2022-08-12 /pmc/articles/PMC9416494/ /pubmed/36014807 http://dx.doi.org/10.3390/nu14163301 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Urasaki, Yasuyo Le, Thuc T. Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation |
title | Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation |
title_full | Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation |
title_fullStr | Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation |
title_full_unstemmed | Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation |
title_short | Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation |
title_sort | cinnamaldehyde and curcumin prime akt2 for insulin-stimulated activation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416494/ https://www.ncbi.nlm.nih.gov/pubmed/36014807 http://dx.doi.org/10.3390/nu14163301 |
work_keys_str_mv | AT urasakiyasuyo cinnamaldehydeandcurcuminprimeakt2forinsulinstimulatedactivation AT lethuct cinnamaldehydeandcurcuminprimeakt2forinsulinstimulatedactivation |